Catalent Pharma Solutions is a leading provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, gene therapies, and consumer health products. The company operates in the Contract Research sector and has a global presence with more than 40 facilities across four continents. Catalent Pharma Solutions is headquartered in Somerset, New Jersey, USA, and has a workforce of over 14,000 employees.

The company's mission is to improve patient outcomes by enabling its customers to develop and deliver innovative treatments that address unmet medical needs. Catalent Pharma Solutions offers a wide range of services, including drug development, manufacturing, packaging, and delivery. The company's expertise in advanced delivery technologies enables it to develop and manufacture complex formulations that improve drug efficacy, safety, and patient compliance.

Catalent Pharma Solutions is committed to sustainability and decarbonisation. The company recognises that climate change is a significant global challenge and is taking steps to reduce its carbon footprint. Catalent Pharma Solutions has set a target to reduce its carbon emissions by 50% by 2030, compared to its 2019 baseline. The company is also committed to sourcing renewable energy to power its operations.

To achieve its decarbonisation goals, Catalent Pharma Solutions is implementing a range of initiatives. The company is investing in energy-efficient technologies and processes to reduce its energy consumption. Catalent Pharma Solutions is also exploring the use of renewable energy sources, such as solar and wind power, to generate electricity for its facilities. The company is also exploring the use of corporate power purchase agreements (PPAs) to source renewable energy.

Corporate PPAs are long-term contracts between a company and a renewable energy project developer. The company agrees to purchase a specified amount of renewable energy from the project developer at a fixed price over a set period. Corporate PPAs enable companies to access renewable energy at a competitive price and provide a stable revenue stream for renewable energy projects.

Catalent Pharma Solutions has already signed a corporate PPA for a 30 MW solar project in North Carolina. The project will generate renewable energy to power the company's facilities in the region. The corporate PPA will provide Catalent Pharma Solutions with a stable source of renewable energy at a competitive price, while also supporting the development of new renewable energy projects.

Catalent Pharma Solutions is also investing in corporate energy management to reduce its energy consumption and carbon emissions. The company has implemented an energy management system that monitors and optimises its energy use. The system enables Catalent Pharma Solutions to identify energy-saving opportunities and implement measures to reduce its energy consumption.

The company has also implemented a range of energy-saving measures, such as upgrading its lighting systems, installing energy-efficient HVAC systems, and optimising its production processes. These measures have enabled Catalent Pharma Solutions to reduce its energy consumption and carbon emissions while also improving its operational efficiency.

In addition to its decarbonisation efforts, Catalent Pharma Solutions is committed to corporate social responsibility. The company is dedicated to promoting diversity, equity, and inclusion in the workplace and the communities where it operates. Catalent Pharma Solutions also supports charitable organisations and initiatives that improve the health and well-being of people around the world.

In conclusion, Catalent Pharma Solutions is a leading provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, gene therapies, and consumer health products. The company operates in the Contract Research sector and has a global presence. Catalent Pharma Solutions is committed to sustainability and decarbonisation and has set a target to reduce its carbon emissions by 50% by 2030. The company is investing in energy-efficient technologies, exploring the use of renewable energy sources, and implementing corporate PPAs to achieve its decarbonisation goals. Catalent Pharma Solutions is also committed to corporate social responsibility and supports initiatives that improve the health and well-being of people around the world.